Shares of Eyenovia Inc (NASDAQ:EYEN) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus price target of $27.50 for the company and are anticipating that the company will post ($0.45) earnings per share for the current quarter, according to Zacks. Zacks has also given Eyenovia an industry rank of 95 out of 255 based on the ratings given to its competitors.
Separately, Zacks Investment Research cut Eyenovia from a “hold” rating to a “sell” rating in a research note on Tuesday, June 19th.
NASDAQ EYEN traded down $0.41 during trading hours on Friday, reaching $4.98. 17,789 shares of the company’s stock were exchanged, compared to its average volume of 10,181. Eyenovia has a one year low of $4.70 and a one year high of $10.74. The stock has a market cap of $51.89 million and a price-to-earnings ratio of -2.27.
Eyenovia (NASDAQ:EYEN) last posted its earnings results on Tuesday, August 14th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.09. analysts anticipate that Eyenovia will post -1.73 EPS for the current fiscal year.
In other Eyenovia news, CEO Tsontcho Ianchulev bought 6,000 shares of the stock in a transaction that occurred on Thursday, June 28th. The stock was acquired at an average cost of $6.63 per share, with a total value of $39,780.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 48.20% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in EYEN. Uniplan Investment Counsel Inc. acquired a new position in Eyenovia during the 1st quarter worth approximately $3,248,000. Millennium Management LLC acquired a new position in Eyenovia during the 1st quarter worth approximately $2,525,000. Highbridge Capital Management LLC acquired a new position in Eyenovia during the 1st quarter worth approximately $1,373,000. Sabby Management LLC acquired a new stake in shares of Eyenovia in the 1st quarter valued at approximately $908,000. Finally, Fairpointe Capital LLC acquired a new stake in shares of Eyenovia in the 2nd quarter valued at approximately $313,000. 12.28% of the stock is owned by hedge funds and other institutional investors.
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
Featured Article: Earnings Per Share
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.